MRKClinical Trials•businesswire•
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
Sentiment:Positive (80)
Summary
(NYSE:MRK) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by businesswire